These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 17215664)

  • 1. Combination ACE inhibitor and angiotensin receptor blocker therapy - future considerations.
    Sica DA
    J Clin Hypertens (Greenwich); 2007 Jan; 9(1):78-86. PubMed ID: 17215664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension.
    Doulton TW; He FJ; MacGregor GA
    Hypertension; 2005 May; 45(5):880-6. PubMed ID: 15809363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors.
    Sica DA
    J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):66-71. PubMed ID: 12228845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
    Messerli FH; Bangalore S; Bavishi C; Rimoldi SF
    J Am Coll Cardiol; 2018 Apr; 71(13):1474-1482. PubMed ID: 29598869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.
    Sakata Y; Shiba N; Takahashi J; Miyata S; Nochioka K; Miura M; Takada T; Saga C; Shinozaki T; Sugi M; Nakagawa M; Sekiguchi N; Komaru T; Kato A; Fukuchi M; Nozaki E; Hiramoto T; Inoue K; Goto T; Ohe M; Tamaki K; Ibayashi S; Ishide N; Maruyama Y; Tsuji I; Shimokawa H; ;
    Eur Heart J; 2015 Apr; 36(15):915-23. PubMed ID: 25637937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Weber MA
    J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ
    Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: its role in clinical practice.
    Sica DA
    J Clin Hypertens (Greenwich); 2003; 5(6):414-20. PubMed ID: 14688498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.
    Volpe M; Tocci G
    Vasc Health Risk Manag; 2012; 8():371-80. PubMed ID: 22745561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARBs vs. ACE inhibitors: which is better for hypertension? ACE inhibitors are generally preferable, but ARBs offer an effective alternative for patients suffering side effects.
    Heart Advis; 2008 Jul; 11(7):4. PubMed ID: 18763362
    [No Abstract]   [Full Text] [Related]  

  • 15. The renin system: is direct renin inhibition different from blockade at the AT1 receptor or the ACE step?
    Hollenberg NK
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S7-13. PubMed ID: 17401314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney disease.
    Linas SL
    Clin J Am Soc Nephrol; 2008 Jan; 3 Suppl 1(Suppl 1):S17-23. PubMed ID: 18178792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in combination: theory and practice.
    Sica DA; Elliott WJ
    J Clin Hypertens (Greenwich); 2001; 3(6):383-7. PubMed ID: 11723362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.
    Reboldi G; Gentile G; Angeli F; Verdecchia P
    Vasc Health Risk Manag; 2009; 5(1):411-27. PubMed ID: 19475778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.
    MacKinnon M; Shurraw S; Akbari A; Knoll GA; Jaffey J; Clark HD
    Am J Kidney Dis; 2006 Jul; 48(1):8-20. PubMed ID: 16797382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.